Advertisement
[adinserter block="11" template="Global Header" check="exceptions" ignore="page-type"]

ASCO GI 2023

Zolbetuximab Plus mFOLFOX6 Scores in Gastric Cancer

Jan 27, 2023

REFERENCES & ADDITIONAL READING

  1. Shitara K, et al. Zolbetuximab + mFOLFOX6 as first-line (1L) treatment for patients (pts) with claudin-18.2+ (CLDN18.2+) / HER2− locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma: Primary results from phase 3 SPOTLIGHT study. Late-breaking abstract 292, ASCO GI, 19–21 January, San Francisco, CA, USA.

Advertisement
[adinserter block="6" template="Meeting Brief Article " check="exceptions" ignore="page-type"]